Name: TONIX PHARMACEUTICALS HOLDIN (TNXP) Stock
Brand: TONIX PHARMACEUTICALS HOLDIN
Rating: 4 (3 reviews)

TNXP Latest News, Press Relases and Analysis

All

Press Releases

15 hours ago - By: Chartmill

TONIX PHARMACEUTICALS HOLDIN (NASDAQ:TNXP) Surges 77% on Q3 Earnings Beat and Key Drug Launch

17 hours ago - By: Tonix Pharmaceuticals Holding Corp.

Tonix Pharmaceuticals Reports Third Quarter 2025 Financial Results and Operational Highlights

7 days ago - By: Tonix Pharmaceuticals Holding Corp.

Tonix Pharmaceuticals Announces Collaboration with Massachusetts General Hospital to Advance Phase 2 Clinical Trial of Dimeric Fc-modified anti-CD40L mAb, TNX-1500, to Prevent Kidney Transplant Organ Rejection

15 days ago - By: Tonix Pharmaceuticals Holding Corp.

Tonix Pharmaceuticals Presented Data on Tonmya™ (Cyclobenzaprine HCl Sublingual Tablets) at the 2025 American College of Rheumatology (ACR) Convergence

20 days ago - By: Tonix Pharmaceuticals Holding Corp.

Tonix Pharmaceuticals Announces First Patient Dosed in the Investigator-Initiated FOCUS Study of Tonix’s Intranasal Potentiated Oxytocin in AVP-D Conducted by Massachusetts General Hospital

21 days ago - By: Tonix Pharmaceuticals Holding Corp.

Tonix Pharmaceuticals to Present Poster on Tonmya™ at the 2025 American College of Rheumatology (ACR) Convergence

25 days ago - By: Tonix Pharmaceuticals Holding Corp.

Tonix Pharmaceuticals Presented Data on TNX-801 Mpox Vaccine at World Vaccine Congress–Europe 2025

a month ago - By: Tonix Pharmaceuticals Holding Corp.

Tonix Pharmaceuticals to Present and Participate in Panel Discussion at World Vaccine Congress, Europe 2025

a month ago - By: Tonix Pharmaceuticals Holding Corp.

Tonix Pharmaceuticals Further Strengthens Commercial Leadership Team with Appointment of Ganesh Kamath as Head of Market Access

a month ago - By: Tonix Pharmaceuticals Holding Corp.

Tonix Pharmaceuticals Plans to Initiate Prader-Willi Syndrome Phase 2 Trial of TNX-2900 (Intranasal Potentiated Oxytocin) in 2026

2 months ago - By: Tonix Pharmaceuticals Holding Corp.

Tonix Pharmaceuticals Announces Positive Pre-IND Meeting with FDA for TNX-102 SL for the Treatment of Major Depressive Disorder

2 months ago - By: Tonix Pharmaceuticals Holding Corp.

Tonix Pharmaceuticals Announces In-licensing Phase 2/3-Ready Monoclonal Antibody Designed for Seasonal Prevention of Lyme Disease (TNX-4800)

3 months ago - By: Benzinga - Mentions: FN AGRO XNET PGEN ...

Fabrinet, Adecoagro And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session

3 months ago - By: Benzinga - Mentions: PPCB GDRX RSKD EMPD ...

Crude Oil Moves Higher; US Homebuilder Sentiment Declines In August

3 months ago - By: Stocktwits - Mentions: UWM IWMW

This Pharma Stock Shot Up 4% Pre-Market After FDA Approval For Drug, Retail’s Super Bullish But Believes ‘This Is A Marathon, Not A Sprint’

3 months ago - By: Tonix Pharmaceuticals Holding Corp.

Tonix Pharmaceuticals Announces FDA Approval of Tonmya™ (cyclobenzaprine HCl sublingual tablets) for the Treatment of Fibromyalgia

3 months ago - By: Stocktwits

Tonix Pharma Scores Best Day Since March On Hopes For First New Fibromyalgia Drug Approval in 16 Years; Retail’s Optimistic

3 months ago - By: Tonix Pharmaceuticals Holding Corp.

Tonix Pharmaceuticals Reports Second Quarter 2025 Financial Results and Operational Highlights

4 months ago - By: Tonix Pharmaceuticals Holding Corp.

Tonix Pharmaceuticals Announces the Launch of the “Move Fibro Forward” Campaign to Bring Awareness to Individuals Impacted by Fibromyalgia

4 months ago - By: Tonix Pharmaceuticals Holding Corp.

TONIX PHARMACEUTICALS HOLDIN (TNXP) Stock News

TNXP Latest News, Press Relases and Analysis

TONIX PHARMACEUTICALS HOLDIN (NASDAQ:TNXP) Surges 77% on Q3 Earnings Beat and Key Drug Launch

Tonix Pharmaceuticals Reports Third Quarter 2025 Financial Results and Operational Highlights

Tonix Pharmaceuticals Announces Collaboration with Massachusetts General Hospital to Advance Phase 2 Clinical Trial of Dimeric Fc-modified anti-CD40L mAb, TNX-1500, to Prevent Kidney Transplant Organ Rejection

Tonix Pharmaceuticals Presented Data on Tonmya™ (Cyclobenzaprine HCl Sublingual Tablets) at the 2025 American College of Rheumatology (ACR) Convergence

Tonix Pharmaceuticals Announces First Patient Dosed in the Investigator-Initiated FOCUS Study of Tonix’s Intranasal Potentiated Oxytocin in AVP-D Conducted by Massachusetts General Hospital

Tonix Pharmaceuticals to Present Poster on Tonmya™ at the 2025 American College of Rheumatology (ACR) Convergence

Tonix Pharmaceuticals Presented Data on TNX-801 Mpox Vaccine at World Vaccine Congress–Europe 2025

Tonix Pharmaceuticals to Present and Participate in Panel Discussion at World Vaccine Congress, Europe 2025

Tonix Pharmaceuticals Further Strengthens Commercial Leadership Team with Appointment of Ganesh Kamath as Head of Market Access

Tonix Pharmaceuticals Plans to Initiate Prader-Willi Syndrome Phase 2 Trial of TNX-2900 (Intranasal Potentiated Oxytocin) in 2026

Tonix Pharmaceuticals Announces Positive Pre-IND Meeting with FDA for TNX-102 SL for the Treatment of Major Depressive Disorder

Tonix Pharmaceuticals Announces In-licensing Phase 2/3-Ready Monoclonal Antibody Designed for Seasonal Prevention of Lyme Disease (TNX-4800)

Fabrinet, Adecoagro And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session

Crude Oil Moves Higher; US Homebuilder Sentiment Declines In August

This Pharma Stock Shot Up 4% Pre-Market After FDA Approval For Drug, Retail’s Super Bullish But Believes ‘This Is A Marathon, Not A Sprint’

Tonix Pharmaceuticals Announces FDA Approval of Tonmya™ (cyclobenzaprine HCl sublingual tablets) for the Treatment of Fibromyalgia

Tonix Pharma Scores Best Day Since March On Hopes For First New Fibromyalgia Drug Approval in 16 Years; Retail’s Optimistic

Tonix Pharmaceuticals Reports Second Quarter 2025 Financial Results and Operational Highlights

Tonix Pharmaceuticals Announces the Launch of the “Move Fibro Forward” Campaign to Bring Awareness to Individuals Impacted by Fibromyalgia

Tonix Pharmaceuticals Announces Presentation of New Data on Mpox and Smallpox Vaccine Candidate TNX-801 at the Vaccine Congress 2025